Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 1
2015 2
2016 2
2017 8
2018 5
2019 6
2020 12
2021 11
2022 12
2023 20
2024 18
2025 16
2026 8

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

110 results

Results by year

Filters applied: . Clear all
Page 1
Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study.
Deodhar A, Sliwinska-Stanczyk P, Xu H, Baraliakos X, Gensler LS, Fleishaker D, Wang L, Wu J, Menon S, Wang C, Dina O, Fallon L, Kanik KS, van der Heijde D. Deodhar A, et al. Ann Rheum Dis. 2021 Aug;80(8):1004-1013. doi: 10.1136/annrheumdis-2020-219601. Epub 2021 Apr 27. Ann Rheum Dis. 2021. PMID: 33906853 Free PMC article. Clinical Trial.
OBJECTIVE: To assess the efficacy/safety of tofacitinib in adult patients with active ankylosing spondylitis (AS). METHODS: This phase III, randomised, double-blind, placebo-controlled study enrolled patients aged 18 years diagnosed with active AS, meeting t …
OBJECTIVE: To assess the efficacy/safety of tofacitinib in adult patients with active ankylosing spondylitis (AS). METH …
Tofacitinib for treating active ankylosing spondylitis.
[No authors listed] [No authors listed] London: National Institute for Health and Care Excellence (NICE); 2023 Oct 18. London: National Institute for Health and Care Excellence (NICE); 2023 Oct 18. PMID: 40198023 Free Books & Documents. Review. No abstract available.
2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis.
Ward MM, Deodhar A, Gensler LS, Dubreuil M, Yu D, Khan MA, Haroon N, Borenstein D, Wang R, Biehl A, Fang MA, Louie G, Majithia V, Ng B, Bigham R, Pianin M, Shah AA, Sullivan N, Turgunbaev M, Oristaglio J, Turner A, Maksymowych WP, Caplan L. Ward MM, et al. Arthritis Care Res (Hoboken). 2019 Oct;71(10):1285-1299. doi: 10.1002/acr.24025. Epub 2019 Aug 21. Arthritis Care Res (Hoboken). 2019. PMID: 31436026 Free PMC article. Review.
OBJECTIVE: To update evidence-based recommendations for the treatment of patients with ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (SpA). METHODS: We conducted updated systematic literature reviews for 20 clinical questions on pharmacolog …
OBJECTIVE: To update evidence-based recommendations for the treatment of patients with ankylosing spondylitis (AS) and nonradi …
Tofacitinib for the treatment of active ankylosing spondylitis in adults.
Mohanakrishnan R, Beier S, Deodhar A. Mohanakrishnan R, et al. Expert Rev Clin Immunol. 2022 Mar;18(3):273-280. doi: 10.1080/1744666X.2022.2038134. Epub 2022 Feb 21. Expert Rev Clin Immunol. 2022. PMID: 35152808
Data regarding efficacy of approved JAK inhibitors in the treatment of ankylosing spondylitis, including tofacitinib, upadacitinib, and filgotinib. EXPERT OPINION: Current treatment options of ankylosing spondylitis include NSAIDs, TNFi, and IL- …
Data regarding efficacy of approved JAK inhibitors in the treatment of ankylosing spondylitis, including tofacitinib, u …
Efficacy and Safety of Tofacitinib in the Management of Ankylosing Spondylitis: A Comprehensive Systematic Review.
Burhanuddin M, Chaudhry SA, Dhami A, Iqbal F, Shafiq S, Ullah S, Khalid A, Hassan MW, Bhatti MM, Siddique MU. Burhanuddin M, et al. Cureus. 2025 Jun 22;17(6):e86556. doi: 10.7759/cureus.86556. eCollection 2025 Jun. Cureus. 2025. PMID: 40698211 Free PMC article. Review.
Ankylosing spondylitis (AS) is a chronic, immune-mediated inflammatory arthritis that can severely impair the quality of life. ...Tofacitinib demonstrated a rapid onset of action, with improvements in pain occurring within one month and benefits across multip …
Ankylosing spondylitis (AS) is a chronic, immune-mediated inflammatory arthritis that can severely impair the quality of life. …
Integrated safety analysis of tofacitinib from Phase 2 and 3 trials of patients with ankylosing spondylitis.
Deodhar A, Akar S, Curtis JR, El-Zorkany B, Magrey M, Wang C, Wu J, Makgoeng SB, Vranic I, Menon S, Fleishaker DL, Diehl AM, Fallon L, Yndestad A, Landewé RBM. Deodhar A, et al. Adv Rheumatol. 2024 Dec 18;64(1):87. doi: 10.1186/s42358-024-00402-x. Adv Rheumatol. 2024. PMID: 39695887
OBJECTIVES: Describe tofacitinib safety from an integrated analysis of randomized controlled trials (RCTs) in patients with ankylosing spondylitis (AS). METHOD: Pooled data from Phase 2 (NCT01786668; 04/2013-03/2015)/Phase 3 (NCT03502616; 06/2018-08/2020) RCT …
OBJECTIVES: Describe tofacitinib safety from an integrated analysis of randomized controlled trials (RCTs) in patients with ankylo …
2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis.
Ward MM, Deodhar A, Gensler LS, Dubreuil M, Yu D, Khan MA, Haroon N, Borenstein D, Wang R, Biehl A, Fang MA, Louie G, Majithia V, Ng B, Bigham R, Pianin M, Shah AA, Sullivan N, Turgunbaev M, Oristaglio J, Turner A, Maksymowych WP, Caplan L. Ward MM, et al. Arthritis Rheumatol. 2019 Oct;71(10):1599-1613. doi: 10.1002/art.41042. Epub 2019 Aug 22. Arthritis Rheumatol. 2019. PMID: 31436036 Free PMC article.
OBJECTIVE: To update evidence-based recommendations for the treatment of patients with ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (SpA). METHODS: We conducted updated systematic literature reviews for 20 clinical questions on pharmacolog …
OBJECTIVE: To update evidence-based recommendations for the treatment of patients with ankylosing spondylitis (AS) and nonradi …
Risk of new-onset and recurrent uveitis with different biologics for ankylosing spondylitis: a network meta-analysis.
Zhao X, Xie Q, He X, Lu Y, Li M, Shuai S. Zhao X, et al. Front Immunol. 2025 Jun 20;16:1556313. doi: 10.3389/fimmu.2025.1556313. eCollection 2025. Front Immunol. 2025. PMID: 40621455 Free PMC article.
BACKGROUND: Uveitis is a common extra-articular manifestation of ankylosing spondylitis (AS), and a systematic analysis of the effects of biologics on new-onset and recurrent uveitis is clinically important. METHODS: We conducted a network meta-analysis (NMA) to ass …
BACKGROUND: Uveitis is a common extra-articular manifestation of ankylosing spondylitis (AS), and a systematic analysis of the …
Cost Effectiveness of Tofacitinib for the Treatment of Active Ankylosing Spondylitis in Greece.
Gourzoulidis G, Solakidi A, Psarra M, Nikitopoulou E, Tzanetakos C. Gourzoulidis G, et al. Clin Drug Investig. 2024 Jan;44(1):59-69. doi: 10.1007/s40261-023-01333-z. Epub 2023 Dec 16. Clin Drug Investig. 2024. PMID: 38104048
BACKGROUND AND OBJECTIVE: Ankylosing spondylitis is a chronic, progressive, inflammatory, multidimensional, musculoskeletal disease primarily involving the axial skeleton. In addition, ankylosing spondylitis is associated with increased morbidity and m …
BACKGROUND AND OBJECTIVE: Ankylosing spondylitis is a chronic, progressive, inflammatory, multidimensional, musculoskeletal di …
Exploring the potential mechanism of tofacitinib therapy for ankylosing spondylitis through gut microbiome and plasma metabolomics.
Wang X, Sun C, Yang X, Xu G, Pei L, Tang L, Xu S, Xie C. Wang X, et al. Clin Rheumatol. 2025 Jul;44(7):2793-2808. doi: 10.1007/s10067-025-07467-z. Epub 2025 May 29. Clin Rheumatol. 2025. PMID: 40439987
OBJECTIVE: To explore the role of gut microbiota and plasma metabolites in the therapeutic mechanism of tofacitinib in ankylosing spondylitis (AS). METHOD: Ten AS patients and ten matched healthy controls (HC) were enrolled in this study. 16S rRNA sequencing …
OBJECTIVE: To explore the role of gut microbiota and plasma metabolites in the therapeutic mechanism of tofacitinib in ankylosing …
110 results